MedTrace Logo

Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors

NCT00800345 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2017-03-28

Study results available
· View outcomes & findings →

Summary

This is a Phase 1, dose-escalation study in female patients with recurrent or persistent gynecologic tumors.

Conditions

  • Gynecologic Tumors

Interventions

DRUG

Oral Topotecan

Starting on Cycle 1 Day 1, each subject will receive the assigned dose of topotecan administered by mouth.

DRUG

Pazopanib

Starting on Cycle 1 Day 1, each subject will receive the assigned dose of pazopanib administered by mouth.

Sponsors & Collaborators

Principal Investigators

  • Todd D Tillmanns, MD · The West Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2015-06-30
Completion
2015-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00800345 on ClinicalTrials.gov